SHALLCROSS STEVEN A (CEO and CFO) purchased 15.6% of their position (25K shares) of THERIVA BIOLOGICS, INC. on the open market
Open‑market purchase worth $23.5K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 2/3/2023ACC: 0001104659-23-010108
DirectorOfficer· CEO and CFO
Since Dec 2018
+25K
Net shares
Net buyer
$23.5K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
25K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+25K
Price / share
$0.94
Trade value
$23.51K
% of position
15.6%
2/2/2023
160K→185K
Total
Net shares
+25K
Net value
$23.51K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/2/2023 | P · Purchase | +25K | $0.94 | $23.51K | 15.6% | 160K | 185K |
| Total | +25K | $23.51K | ||||||
Derivative Transactions0
No derivative transactions reported